Table 2 Clinical and laboratory data of the de novo patients
Variables | De novo [N = 46] |
|---|---|
Clinical data | |
Age [years (mean ± SD)] | 6.685 ± 3.028 |
Sex | |
Male [N (%)] | 36 (78.3%) |
Female [N (%)] | 10 (21.7%) |
Pallor [N (%)] | 32 (69.4%) |
Dyspnea [N (%)] | 15 (32.6%) |
Fever [N (%)] | NA |
Bleeding [N (%)] | 1 (2.2%) |
Bony pains [N (%)] | 3 (6.5%) |
Lymphadenopathy [N (%)] | 3 (6.5%) |
CNS infiltration [N (%)] | 1 (2.2%) |
Laboratory data | |
WBCs at initial diagnosis [× 109/L (mean ± SD)] | 125.01 ± 151.372 |
Blast count at initial diagnosis [% (mean ± SD)] | 65.96 ± 24.87 |
Hemoglobin at initial diagnosis [g/dL (mean ± SD)] | 8.07 ± 1.85 |
Platelets at initial diagnosis [× 109/L (mean ± SD)] | 40.46 ± 27.57 |
FAB classification | |
L1 [N (%)] | 19 (41.3%) |
L2 [N (%)] | 27 (58.7%) |
Immune-phenotyping | |
B-ALL | |
Pre-B-ALL [N (%)] | 15 (32.6%) |
Common B-ALL [N (%)] | 14 (30.4%) |
T-ALL | |
Early T-ALL [N (%)] | 5 (10.8%) |
Intermediate T-ALL [N (%)] | 9 (19.5%) |
Late T-ALL [N (%)] | 3 (6.5%) |
Cytogenetic | |
t(1;19) [N (%)] | 0% |
t(4;11) [N (%)] | 0% |
t(12;21) [N (%)] | 0% |
t(9;22), p190 kD [N (%)] | 0% |
t(9;22), p210 kD [N (%)] | 0% |